[{"address1": "12278 Scripps Summit Drive", "city": "San Diego", "state": "CA", "zip": "92131", "country": "United States", "phone": "858 875 1800", "website": "https://www.fatetherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Mr. J. Scott Wolchko", "age": 53, "title": "Founder, CEO, CFO, President, Principal Financial & Accounting Officer and Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 920400, "exercisedValue": 0, "unexercisedValue": 50500}, {"maxAge": 1, "name": "Ms. Cindy R. Tahl J.D.", "age": 50, "title": "General Counsel, Corporate Secretary & Compliance Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 612500, "exercisedValue": 0, "unexercisedValue": 25250}, {"maxAge": 1, "name": "Dr. Bahram  Valamehr Ph.D.", "age": 46, "title": "Chief Research & Development Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 644500, "exercisedValue": 0, "unexercisedValue": 13288}, {"maxAge": 1, "name": "Mr. Jim  Beitel M.B.A.", "title": "Senior Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jerome  Bressi Ph.D.", "title": "Senior Vice President of Regulatory & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 3, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.37, "open": 3.44, "dayLow": 3.23, "dayHigh": 3.441, "regularMarketPreviousClose": 3.37, "regularMarketOpen": 3.44, "regularMarketDayLow": 3.23, "regularMarketDayHigh": 3.441, "beta": 1.899, "forwardPE": -1.7837838, "volume": 1008699, "regularMarketVolume": 1008699, "averageVolume": 2158537, "averageVolume10days": 2165440, "averageDailyVolume10Day": 2165440, "bid": 3.3, "ask": 3.31, "bidSize": 100, "askSize": 200, "marketCap": 375645600, "fiftyTwoWeekLow": 1.63, "fiftyTwoWeekHigh": 8.83, "priceToSalesTrailing12Months": 57.987896, "fiftyDayAverage": 3.9588, "twoHundredDayAverage": 4.47055, "currency": "USD", "enterpriseValue": 102142736, "floatShares": 90486170, "sharesOutstanding": 113832000, "sharesShort": 20285819, "sharesShortPriorMonth": 21149099, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.17819999, "heldPercentInsiders": 0.01932, "heldPercentInstitutions": 1.1196901, "shortRatio": 9.8, "shortPercentOfFloat": 0.2045, "bookValue": 3.744, "priceToBook": 0.88141024, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -190051008, "trailingEps": -1.92, "forwardEps": -1.85, "pegRatio": 0.05, "enterpriseToRevenue": 15.768, "enterpriseToEbitda": -0.564, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "FATE", "underlyingSymbol": "FATE", "shortName": "Fate Therapeutics, Inc.", "longName": "Fate Therapeutics, Inc.", "firstTradeDateEpochUtc": 1380634200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "98fe3f7f-5aa9-30d5-b866-ea8a0474dc72", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.3, "targetHighPrice": 12.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.79, "targetMedianPrice": 6.0, "recommendationMean": 2.6, "recommendationKey": "hold", "numberOfAnalystOpinions": 14, "totalCash": 383544000, "totalCashPerShare": 3.369, "ebitda": -181175008, "totalDebt": 102070000, "quickRatio": 8.493, "currentRatio": 8.693, "totalRevenue": 6478000, "debtToEquity": 23.954, "revenuePerShare": 0.065, "returnOnAssets": -0.20838, "returnOnEquity": -0.42066002, "freeCashflow": -51696376, "operatingCashflow": -136752992, "revenueGrowth": -0.967, "operatingMargins": -26.528831, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-12"}]